

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028458 A3

(51) International Patent Classification:

C07D 401/14 (2006.01) A61P 25/18 (2006.01)
A61P 25/00 (2006.01) A61P 25/28 (2006.01)
A61P 25/04 (2006.01) A61K 31/454 (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:

PCT/EP2023/071591

(22) International Filing Date:

03 August 2023 (03.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2211399.7	04 August 2022 (04.08.2022)	GB
2305444.8	13 April 2023 (13.04.2023)	GB
2309615.9	26 June 2023 (26.06.2023)	GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**
[GB/GB]; Granta Park, Great Abington, Cambridge Cam-
bridgeshire CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Ther-
apeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **MC GEE, Paul**;
c/o Heptares Therapeutics Limited, Granta Park, Great
Abington, Cambridge Cambridgeshire CB21 6DG (GB).
CANSFIELD, Julie; c/o Heptares Therapeutics Limited,
Granta Park, Great Abington, Cambridge Cambridgeshire
CB21 6DG (GB). **PICKWORTH, Mark**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(88) Date of publication of the international search report:

21 March 2024 (21.03.2024)

(54) Title: CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST

(57) Abstract: This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts thereof; pharmaceutical compositions containing the compounds and salts thereof, or crystalline forms thereof; therapeutic uses of the compounds and salts thereof, or crystalline forms thereof; methods of synthesis thereof; and intermediates useful in said methods of synthesis.

WO 2024/028458 A3